NICE has issued draft guidance not recommending Perjeta (pertuzumab), from Roche, to treat HER2-positive breast cancer because it is uncertain...
The EU has approved the use of Perjeta (pertuzumab), from Roche, in combination with Herceptin (trastuzumab) and chemotherapy for the...
An FDA advisory panel has voted in favor of recommending accelerated approval of Perjeta (pertuzumab), from Roche, as a neoadjuvant...
The FDA has approved Phesgo (pertuzumab + trastuzumab + hyaluronidase–zzxf), from Genentech/Roche, for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer.
Genentech, announced the FDA has accepted the company�s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta (pertuzumab),...
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tukysa (tucatinib + trastuzumab + capecitabine), from Seagen, for the treatment of advanced HER2-positive breast cancer.
The FDA on 30 September 2013, granted accelerated approval to Perjeta (pertuzumab) from Genentech/Roche as part of a complete treatment...
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone receptor (HR)-positive, HER2-negative breast cancer following progression after treatment with endocrine therapy.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.